Skip to main content
. Author manuscript; available in PMC: 2019 Oct 30.
Published in final edited form as: Leukemia. 2019 Mar 11;33(9):2266–2275. doi: 10.1038/s41375-019-0435-7

Figure 1–

Figure 1–

OS of MM patients refractory to CD38 MoAB according to refractoriness to PIs and IMiDs (panel a), cytogenetic risk (panel b), LDH (panel c) and renal function (panel d) at time of initiation of index regimen.